Kiniksa Pharmaceuticals International (KNSA) Non-Current Assets (2017 - 2026)

Kiniksa Pharmaceuticals International's Non-Current Assets history runs 10 years deep, the most recent figure standing at $231.1 million for Q1 2026.

• Quarterly Non-Current Assets fell 5.06% year-over-year to $231.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $945.2 million (down 3.31% YoY) and the FY2025 annual result came in at $236.5 million, down 4.94% from the prior year.
• Non-Current Assets was $231.1 million for Q1 2026 at Kiniksa Pharmaceuticals International, down from $236.5 million in the prior quarter.
• Across five years, Non-Current Assets topped out at $250.0 million in Q4 2023 and bottomed at $30.6 million in Q2 2022.
• A 5-year average of $211.5 million and a median of $236.8 million in 2025 frame the typical range for Non-Current Assets.
• Annual changes were most pronounced in 2022 — Non-Current Assets dropped 10.93% — and 2023, when it soared 677.77%.
• Kiniksa Pharmaceuticals International's Non-Current Assets stood at $216.6 million in 2022, then gained by 15.43% to $250.0 million in 2023, then slipped by 0.51% to $248.8 million in 2024, then slipped by 4.94% to $236.5 million in 2025, then declined by 2.26% to $231.1 million in 2026.
• Business Quant data shows KNSA's Non-Current Assets at $231.1 million in Q1 2026, $236.5 million in Q4 2025, and $236.8 million in Q3 2025.